Literature DB >> 17090573

Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?

David M Mannino1, A Sonia Buist, William M Vollmer.   

Abstract

BACKGROUND: The Global Initiative on Obstructive Lung Disease stages for chronic obstructive pulmonary disease (COPD) uses a fixed ratio of the post-bronchodilator forced expiratory volume in 1 second (FEV(1))/forced vital capacity (FVC) of 0.70 as a threshold. Since the FEV(1)/FVC ratio declines with age, using the fixed ratio to define COPD may "overdiagnose" COPD in older populations.
OBJECTIVE: To determine morbidity and mortality among older adults whose FEV(1)/FVC is less than 0.70 but more than the lower limit of normal (LLN).
METHODS: The severity of COPD was classified in 4965 participants aged > or =65 years in the Cardiovascular Health Study using these two methods and the age-adjusted proportion of the population who had died or had a COPD-related hospitalisation in up to 11 years of follow-up was determined.
RESULTS: 1621 (32.6%) subjects died and 935 (18.8%) had at least one COPD-related hospitalisation during the follow-up period. Subjects (n = 1134) whose FEV(1)/FVC fell between the LLN and the fixed ratio had an increased adjusted risk of death (hazard ratio (HR) 1.3, 95% CI 1.1 to 1.5) and COPD-related hospitalisation (HR 2.6, 95% CI 2.0 to 3.3) during follow-up compared with asymptomatic individuals with normal lung function.
CONCLUSION: In this cohort, subjects classified as "normal" using the LLN but abnormal using the fixed ratio were more likely to die and to have a COPD-related hospitalisation during follow-up. This suggests that a fixed FEV(1)/FVC ratio of <0.70 may identify at-risk patients, even among older adults.

Entities:  

Mesh:

Year:  2006        PMID: 17090573      PMCID: PMC2117148          DOI: 10.1136/thx.2006.068379

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  19 in total

1.  Nosology for our day: its application to chronic obstructive pulmonary disease.

Authors:  Gordon L Snider
Journal:  Am J Respir Crit Care Med       Date:  2003-03-01       Impact factor: 21.405

2.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

3.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

4.  Usefulness of GOLD classification of COPD severity.

Authors:  D Köhler; J Fischer; F Raschke; B Schönhofer
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 5.  Low vision in the geriatric population: rehabilitation and management.

Authors:  G R Watson
Journal:  J Am Geriatr Soc       Date:  2001-03       Impact factor: 5.562

6.  Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study.

Authors:  A Johannessen; E R Omenaas; P S Bakke; A Gulsvik
Journal:  Thorax       Date:  2005-08-05       Impact factor: 9.139

Review 7.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 8.  Worldwide epidemiology of chronic obstructive pulmonary disease.

Authors:  J C Chen; D M Mannino
Journal:  Curr Opin Pulm Med       Date:  1999-03       Impact factor: 3.155

9.  Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers.

Authors:  J A Hardie; A S Buist; W M Vollmer; I Ellingsen; P S Bakke; O Mørkve
Journal:  Eur Respir J       Date:  2002-11       Impact factor: 16.671

10.  Chronic obstructive pulmonary disease surveillance--United States, 1971-2000.

Authors:  David M Mannino; David M Homa; Lara J Akinbami; Earl S Ford; Stephen C Redd
Journal:  MMWR Surveill Summ       Date:  2002-08-02
View more
  64 in total

1.  Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study.

Authors:  Tuula Toljamo; Marjo Kaukonen; Pentti Nieminen; Vuokko L Kinnula
Journal:  Scand J Prim Health Care       Date:  2010-03       Impact factor: 2.581

2.  Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality.

Authors:  Surya P Bhatt; Pallavi P Balte; Joseph E Schwartz; Patricia A Cassano; David Couper; David R Jacobs; Ravi Kalhan; George T O'Connor; Sachin Yende; Jason L Sanders; Jason G Umans; Mark T Dransfield; Paulo H Chaves; Wendy B White; Elizabeth C Oelsner
Journal:  JAMA       Date:  2019-06-25       Impact factor: 56.272

3.  Definition of COPD GOLD stage I.

Authors:  Edward L Petsonk; Eva Hnizdo; Michael Attfield
Journal:  Thorax       Date:  2007-12       Impact factor: 9.139

4.  GOLD stage I is not a COPD risk factor.

Authors:  Paul L Enright
Journal:  Thorax       Date:  2007-12       Impact factor: 9.139

5.  What defines abnormal lung function?

Authors:  Martin R Miller
Journal:  Thorax       Date:  2007-12       Impact factor: 9.139

6.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

7.  The ratio of FEV1 to FVC as a basis for establishing chronic obstructive pulmonary disease.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Carolyn L Rochester; H Klar Yaggi; Thomas M Gill
Journal:  Am J Respir Crit Care Med       Date:  2009-12-17       Impact factor: 21.405

8.  Treatment of chronic obstructive pulmonary disease in hospitalized geriatric patients.

Authors:  J Schlitzer; S Haubaum; H Frohnhofen
Journal:  Z Gerontol Geriatr       Date:  2014-06       Impact factor: 1.281

9.  The prognostic significance of lung function in stable heart failure outpatients.

Authors:  Louis Lind Plesner; Morten Dalsgaard; Morten Schou; Lars Køber; Jørgen Vestbo; Erik Kjøller; Kasper Iversen
Journal:  Clin Cardiol       Date:  2017-09-13       Impact factor: 2.882

10.  Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS.

Authors:  Carlos H Martinez; Alejandro A Diaz; Catherine Meldrum; Jeffrey L Curtis; Christopher B Cooper; Cheryl Pirozzi; Richard E Kanner; Robert Paine; Prescott G Woodruff; Eugene R Bleecker; Nadia N Hansel; R Graham Barr; Nathaniel Marchetti; Gerard J Criner; Ella A Kazerooni; Eric A Hoffman; Brian D Ross; Craig J Galban; Christine T Cigolle; Fernando J Martinez; MeiLan K Han
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.